An evidence index for under-researched women’s health conditions.
Women’s health conditions are persistently underfunded, undertreated, and under-diagnosed. Endometriosis affects roughly 1 in 10 reproductive-age women yet averages 7 to 10 years to diagnosis. PCOS, the most common endocrine disorder of reproductive age, has no FDA-approved therapy. These are the conditions medicine has been slow to study.
Whel aggregates four parallel streams of evidence, scores each signal across five dimensions, and publishes the result with full provenance, for clinicians, researchers, and informed patients to interpret.
Women’s health conditions are persistently underfunded, undertreated, and under-diagnosed. Endometriosis affects roughly 1 in 10 reproductive-age women yet averages 7 to 10 years to diagnosis. PCOS, the most common endocrine disorder of reproductive age, has no FDA-approved therapy. These are the conditions medicine has been slow to study.
Whel aggregates four parallel streams of evidence, scores each signal across five dimensions, and publishes the result with full provenance, for clinicians, researchers, and informed patients to interpret.
- Signals indexed
- 281
- Conditions covered
- 6
- Strong-tier
- 28
- Last review
- May 2026
Where the evidence sits, by condition.
How signals flow from source to tier.
Each curve is one provenance pathway. Tier node heights are proportional to signal count. Direct Research dominates the Strong tier; Pathway Insights and Community Forum signals concentrate in Emerging and Exploratory. ↑ Ribbon thickness scales with signal volume.
How evidence is evaluated
Every signal in Whel is scored before it enters the database. Each record is assessed across five dimensions: replication, source quality, specificity, biological plausibility, and consistency of direction. Each dimension is rated 0 to 2, summed to a 0 to 10 composite. Results are classified into a confidence tier, and sources and scores are visible on every card.
Conditions covered.
Adenomyosis
Endometriosis
PCOS
Perimenopause & Menopause
PMDD
Vulvodynia
How signals are categorized
Direct Research
Published studies and active clinical trials specifically investigating each condition.
Cross-Condition Signals
Drugs developed for other conditions where women incidentally reported benefit.
Pathway Insights
Signals from biological pathway and target analysis, including drugs with mechanistic or genetic evidence of relevance, and adverse event patterns revealing underlying disease biology.
Community Forum Reports
Consistent treatment patterns reported across condition-specific patient communities.